Northwest BiotherapeuticsNWBO
13F holders, Q2 2024 (June 30)13holders +3
2new positions
0sold out
$0.43avg. 13F price*
At the end of Q2 2024, 13 institutions reported holding Northwest Biotherapeutics (NWBO) in their 13F filings, up 3 from Q1 2024. 2 opened new positions and 0 sold out. The largest holders were Moloney Securities Asset Management, LLC ($181K), Opus Capital Group, LLC ($26K) and Maripau Wealth Management LLC ($17K).
- Company
- Northwest Biotherapeutics
- Filed as
- NW Biotherapeutics (Q2 2024)
- CUSIP
- 66737P600
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $10K |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 67,775 shares bought and 5,000 shares sold, net +62,775 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 13 holders
| Moloney Securities Asset Management, LLC | 0.03% | Add +11.8% | 424,310 | $181K |
| Opus Capital Group, LLC | 0.00% | No change | 60,150 | $26K |
| Maripau Wealth Management LLC | 0.01% | No change | 39,493 | $17K |
| Williams Jones Wealth Management, LLC. | 0.00% | Reduce -12.5% | 35,000 | $15K |
| Ethos Financial Group, LLC | 0.00% | No change | 23,700 | $10K |
| Lee Danner & Bass Inc. | 0.00% | — | 20,000 | $9K |
| MAI Capital Management | 0.00% | No change | 20,000 | $9K |
| AlphaMark Advisors, LLC | 0.00% | No change | 14,007 | $6K |
| Rothschild Wealth LLC | 0.00% | New | 12,925 | $6K |
| KLCM Advisors, Inc. | 0.00% | New | 10,000 | $4K |
| Advisors Management Group Inc. | 0.00% | No change | 10,270 | $4K |
| Hantz Financial Services, Inc. | 0.00% | No change | 250 | $0 |
| Coston, McIsaac & Partners | 0.00% | No change | 1,000 | $0 |
"% of holder's portfolio" is NWBO's weight in each manager's 13F, not the share of Northwest Biotherapeutics the manager owns.